前列通瘀胶囊联合前列安栓治疗慢性前列腺炎46例的疗效观察

目的：观察前列通瘀胶囊联合前列安栓治疗慢性前列腺炎的疗效。方法：86例患者随机分为两组，治疗组采用口服前列通瘀胶囊，同时前列安栓纳肛，对照组口服罗红霉素片，两组一个月为一疗程。观察用药前后慢性前列腺炎症状平分（CPSI），以及前列腺液中白细胞和卵磷脂小体改善的状况。结果：前列通瘀胶囊联合前列安栓能降低慢性前列腺炎的症状和前列腺液中的白细胞，增多卵磷脂小体较明显。罗红霉素只能降低前列腺液中的白细胞，对其它指标改善不明显。结论：前列通瘀胶囊联合前列安栓治疗慢性前列腺炎的疗效确切。     

前列安栓治疗慢性前列腺炎疗效观察

目的：评价前列安栓局部纳肛治疗慢性前列腺炎的疗效及不良反应。方法：将患者随机分为两组进行开放对比观察，治疗组70例用前列安栓纳肛，连续1个月，对照组35例口服司巴沙星，连用2周，根据前列腺按摩液EPS—WBC和美国国立卫生院(NIH)慢性前列腺炎症状评分表中的症状评分评价疗效。结果：对观察指标分析显示，前列安栓临床痊愈11例(16．1％)、显效19例(27．9％)、有效26例(38．2％)，疗效明显优于对照组，且不良反应轻微。结论：前列安栓局部纳肛治疗慢性前列腺炎有明显效果，不良反应低。     

前列饮治疗性病后慢性前列腺炎40例

性病后慢性前列腺炎,病程迁延,症状反复,治疗较为棘手。我们自1998年2月至2000年9月应用自拟中药前列饮治疗性病后慢性衣原体性、支原体性前列腺炎40例,疗效满意,现报道如下。1 临床资料1.1 一般情况 本组40例均为门诊病例。年龄     

壮药前列舒外洗剂对慢性前列腺炎的临床观察

目的：观察壮药前列舒外洗剂对慢性前列腺炎的临床疗效。方法：将360例湿热挟瘀证慢性前列腺炎患者按症状分为Ⅱ、ⅢA 和ⅢB型,各型又随机分为治疗组和对照组,治疗组予以壮药前列舒外洗剂,对照组予以前列安栓,两组均以28d为1个疗程。观察各组患者的中医证候学评分、NIH-CPSI评分及白细胞计数,判断临床疗效。结果：治疗后,在总有效率、中医证候学评分、NIH-CPSI评分及白细胞计数变化方面差异有统计学意义,治疗组疗效优于对照组。结论：壮药前列舒外洗剂对慢性前列腺炎有较好的疗效。     

慢性前列腺炎的诊疗和治疗

慢性前列腺炎是泌尿外科最常见的疾病之一,它虽然不会对患者生命直接造成威胁,但可以严重影响患者的生活质量。目前慢性前列腺炎的病因不明,诊断缺乏金标准,治疗亦无特效疗法。本文强调诊断应以NIH-CPSI症状评分为主;治疗采取综合疗法,制定个体化方案,重视心理治疗;疗效评价以症状改善、提高生活质量为目的。     

前列舒通胶囊合用喹诺酮类抗生素治疗慢性细菌性前列腺炎的临床研究

目的:观察前列舒通胶囊联合喹诺酮类抗生素治疗慢性细菌性前列腺炎的临床疗效及安全性,为慢性细菌性前列腺炎的治疗提供参考。方法:选择我院2015年2月至2016年1月门诊收治的80例慢性细菌性前列腺炎患者作为研究对象,根据所采用的治疗方法的不同,将其分为对照组和观察组,对照组44例采用喹诺酮类抗生素治疗,观察组36例采用前列舒通胶囊联合喹诺酮类抗生素治疗,两组患者均连续治疗8周。采用美国国立卫生院制定的《慢性前列腺症状指数评分》(NIH-CPSI)对两组患者治疗前、治疗4周、治疗8周的症状进行评价比比较,对两组患者治疗前后的前列腺按摩液进行白细胞计数检查并比较,两组患者治疗8周后采用NIH-CPSI与前列腺按摩液白细胞计数指标判断临床疗效并比较,统计两组患者治疗期间的不良反应并比较。结果:两组患者治疗前NIH-CPSI评分、前列腺按摩液白细胞计数比较差异均无统计学意义(P0.05);两组患者治疗4周、8周后NIH-CPSI指数与前列腺按摩液白细胞计数均较治疗前明显降低,且治疗后观察组NIH-CPSI与前列腺按摩液白细胞计数明显低于对照组(P0.05)。治疗8周后两组患者临床总有效率比较,观察组总有效率明显高于对照组(P0.05)。两组患者治疗期间未收集到明显的不良反应。结论:前列舒通胶囊辅助喹诺酮类抗生素治疗慢性细菌性前列腺炎临床疗效确切,安全性高,具有较高的临床价值。     

前列清瘀汤治疗慢性前列腺炎78例

目的:观察前列清瘀汤治疗慢性前列腺炎的临床疗效特点.方法:78例慢性前列腺炎患者给予前列清瘀汤煎服,观察疗效特点.结果:6周后,所有患者中医症候均得到明显改善,NIH - CPSI评分、EPS镜检WBC不同程度降低,有效率为96.9％.结论:前列清瘀汤治疗症候复杂性慢性前列腺炎疗效显著.     

通前络汤与前列倍喜胶囊治疗慢性前列腺炎的比较分析

目的:研究通前络汤在慢性前列腺炎患者中的临床疗效,为临床提供依据。方法:选取2014年1月至2016年5月医院诊治的慢性前列腺炎患者100例,根据治疗措施将患者分为对照组50例和观察组50例。对照组口服前列倍喜胶囊治疗,3次/d,2g/次;观察组通前络汤治疗,1剂/d,250mL/次,分早晚服用,比较两组临床疗效。结果:两组治疗前疼痛不适、排尿情况、症状影响、生活质量及总评分差异无统计学意义(P0.05);观察组治疗后疼痛不适、排尿情况、症状影响、生活质量及总评分,显著低于对照组(P0.05);两组患者治疗前炎症指标IL-8、TNF-α及IFN-γ水平差异无统计学意义(P0.05);观察组治疗后炎症指标IL-8、TNF-α及IFN-γ水平,显著低于对照组(P0.05)。结论:与前列倍喜胶囊治疗相比,慢性前列腺炎患者采用通前络汤治疗效果理想,能改善患者症状,减轻炎症指标,值得推广应用。     

慢性前列腺炎患者实施水蛭蜈蚣栓加入微波治疗的效果

目的:探讨慢性前列腺炎患者实施水蛭蜈蚣栓加入微波治疗的效果。方法:对泸州市中医医院2015年4月至2017年4月收治的80例慢性前列腺炎患者的临床资料进行统计分析,依据治疗方法将这些患者分为水蛭蜈蚣栓加入微波治疗组(联合治疗组,n=40)和单独微波治疗组(单独治疗组,n=40)两组,对两组患者的临床症状、临床疗效、性生活质量进行统计分析。结果:联合治疗组患者的疼痛或不适、排尿异常、生活质量评分及NIH-CPSI总分均显著低于单独治疗组,差异具有统计学意义(P <0. 05),治疗的总有效率90. 0%(36/40)显著高于单独治疗组72. 5%(29/40),差异具有统计学意义(P <0. 05),性欲、性唤起、性高潮、性生活频率、性生活接受度、性关系满意度评分均显著高于单独治疗组,差异具有统计学意义(P<0. 05),性行为症状发生比例评分显著低于单独治疗组,差异具有统计学意义(P <0. 05)。结论:慢性前列腺炎患者实施水蛭蜈蚣栓加入微波治疗的效果较单独微波治疗好。     

慢性前列腺炎症状的严重度与前列腺液白细胞数量及病原体相关性研究

目的:探讨前列腺液(EPS)中的白细胞计数、病原体与症状的严重程度的相关性。方法:嘱102例符合入选标准的慢性前列腺炎(chronic prostatitis,CP)患者,认真阅读、填写美国国立卫生研究院制定的CP症状指数(The National Institutes of Health Chronic Prostatitis Symptom Index,NIH-CPSI)表1。采用“四杯法”分别收集尿液和EPS,并进行相关实验室检测。结果:102例患者,慢性前列腺炎症状指数(CPSI)总得分:最低为2分,最高为43分,平均20.4±8.23分;EPS病原体阳性者46例(45.1%);EPS白细胞≥10个/HP者50例(49%),<10个/HP者52例(51%)。结论:患者临床症状的严重程度与EPS中白细胞数量、病原体感染之间并无明显相关性。     

腔道介入治疗慢性前列腺炎200例临床效果分析

目的:探究应用腔道介入的方法治疗慢性前列腺炎的临床疗效。方法:随机选取2009年6月至2011年12月期间在我院门诊就诊并且经药物治疗无效的患有慢性前列腺炎的患者200例,对这200例患者进行腔道介入疗法进行治疗,观察并记录治疗的效果。结果:观察的200例患者中,经过治疗后治疗效果均比较明显,症状均有所好转,治愈率达到60%,明显好转率为17.3%。结论:治疗慢性前列腺炎时使用腔道介入疗法进行治疗,能够收到比较好的疗效,治愈率较高,安全性好。腔道介入疗法为前列腺炎的患者提供了一条新型、有效并且安全的治疗途径。     

慢性前列腺炎症状评分与前列腺液白细胞及卵磷脂小体数量相关性分析

目的：探讨前列腺液（EPS）中白细胞（WBC）及卵磷脂小体（SPL）数量与症状严重程度的相关性。方法：164例慢性前列腺炎（CP）患者填写慢性前列腺炎症状评分（CPSI）,EPS常规检测WBC及SPL数量,对CPSI评分与EPS中WBC及SPL数量的关系进行统计学分析。结果：CPSI评分与EPS中WBC及SPL数量之间无线性关系（P〉0．05）,WBC数量和SPL数量之间高度负相关（P〈0．001）。结论：EPS中WBC及SPL数量与症状严重程度无相关性,不适合作为CP诊断及疗效评价的指标。慢性前列腺炎的诊断和疗效评价应该以临床症状为主。     

三金片、金匮肾气丸联合抗生素治疗老年慢性前列腺炎临床观察

目的：观察三金片、金匮肾气丸联合抗生素治疗老年慢性前列腺炎临床疗效。方法：门诊慢性前列腺炎患者随机分为两组：抗生素治疗组（52例）,给予左氧氟沙星片与罗红霉素片口服;联合治疗组（56例）,给予三金片、金匮肾气丸与左氧氟沙星、罗红霉素同时口服治疗。连续治疗30d观察疗效和NIH—CPSI积分。结果：两组临床疗效总有效率、愈显率比较P〈0．05;两组治疗后NIH—CPSI积分均较治疗前有不同程度的改善P〈0．01,联合治疗组改善更明显P〈0．05。结论：三金片、金匮肾气丸联合抗生素治疗老年慢性前列腺炎安全有效。     

咪唑斯汀治疗慢性荨麻疹临床试验

目的:评价咪唑斯汀(mizolastine,皿治林)治疗慢性荨麻疹的疗效和安全性。方法:用多中心、开放性的方法对患者服用咪唑斯汀10mg,每日1次,连续服用14天,进行疗效评价。结果:可分析病例1390例,男性594例,女性796例。治疗第7天,疾病总积分由治疗前的7.7259±0.0379下降为3.1388±0.0605,差异有显著性(P<0.001)。21.7%获痊愈,23.2%获显效,有效率44.8%。治疗第14天时,总积分进一步下降为1.3813±0.0517,与治疗前比较差异有显著性(P<0.001)。54.7%获痊愈,27.2%获显效,有效率81.9%。不良反应发生率为11.3%,均为轻微和可逆性反应。结论:咪唑斯汀治疗慢性荨麻疹疗效肯定,安全性高。     

The clinical anti-aging effects of topical kinetin and niacinamide in Asians: a randomized, double-blind, placebo-controlled, split-face comparative trial

Background Kinetin and niacinamide are used in the cosmetic industry as anti‐aging agents. Neither the interactive/additive effects of these compounds nor the anti‐aging efficacy on Asian skin has been studied. Objective To assess the clinical anti‐aging effects and efficacy differences between kinetin plus niacinamide and niacinamide alone vs. vehicle placebo in an Asian cohort. Methods Fifty‐two Taiwanese subjects were enrolled in a randomized, double‐blind, placebo‐controlled, split‐face comparative study. Group 1 subjects were treated with kinetin 0.03% plus niacinamide 4%, whereas group 2 subjects received niacinamide 4%. The treatment formulation was applied on one side of the face, whereas a placebo was applied on the other for a period of 12 weeks. We used noninvasive biometrological instruments to evaluate a variety of skin parameters at baseline and at weeks 4, 8, and 12. Results Persistent and significant reductions in spot, pore, wrinkle, and evenness counts were found at weeks 8 and 12 in group 1. A significant increase in corneal hydration status was also evident at week 12, whereas persistent decreases in erythema index were apparent at 8 and 12 weeks. In group 2, significant reductions in pore and evenness counts at week 8 and wrinkle counts at week 12 were noted. Conclusion We found kinetin and niacinamide exert a synergistic anti‐aging effect. Our data suggest that these compounds have multiactive, multifunctional, and pluripotent effects on skin. They are also both promising to be included in the cutaneous anti‐aging cosmeceuticals in the future.     

Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study

BACKGROUND: Chronic urticaria is a common skin condition. It is frequently a disabling disease because of the persistence of clinical symptoms, the unpredictable course and its negative influence on the quality of life. OBJECTIVES: To determine whether levocetirizine is efficacious in the treatment of chronic idiopathic urticaria. METHODS: A randomized, double-blind, placebo-controlled study was conducted in 106 patients with a diagnosis of chronic idiopathic urticaria. A 1-week single blind placebo run-in period (baseline) was followed by a 6-week double blind active treatment period. The patients were randomized to receive one of the following treatments once daily: (a) oral levocetirizine 5 mg, or (b) oral placebo. The study ended after another 1-week single blind placebo washout period. RESULTS: The evaluable population consisted of 100 patients. Levocetirizine administered once daily is effective and well tolerated in the treatment of the symptoms of chronic idiopathic urticaria and in improving the patient's quality of life. Levocetirizine was superior to placebo in reducing the mean total symptoms score as well as individual symptoms, the number of daily episodes and the number of weals, the overall severity of symptoms and the quality of life. The significant beneficial effects of levocetirizine lasted only during the active trial, while at follow-up there was a significant worsening of all the variables evaluated in this study, after the end of the active trial (week 7). CONCLUSIONS: A global assessment indicates that levocetirizine 5 mg once daily is an effective agent in patients with chronic idiopathic urticaria, as its action provides a rapid and satisfactory control of the symptoms and measures of subjective disease, although this is limited to the duration of treatment.     

前炎止痛贴联合前列清瘀汤治疗慢性前列腺炎疗效评价及对EPS中Zn2+和PSA水平的影响

目的观察前炎止痛贴联合前列清瘀汤治疗慢性前列腺炎的临床疗效及对前列腺液中锌离子(Zn2+)和前列腺特异性抗原(prostate-specific antigen,PSA)水平的影响。方法选取2018年1月至10月湖南中医药大学第一附属医院诊治的160例符合标准的慢性前列腺炎(湿热夹瘀型)患者为研究对象,将其随机分为脐贴+中药组、脐贴组、中药组、宁泌泰胶囊组4组,每组40例患者,比较各组患者治疗前后前列腺液中Zn2+和PSA水平及其临床疗效。结果①四组患者治疗后疗效比较存在差异,脐贴+中药组患者治疗后的总有效率(92.5%)明显优于其他各组患者,其差异均具有统计学意义(均P<0.05);②四组患者治疗后前列腺液中Zn2+和PSA水平均明显高于治疗前,其差异均具有统计学意义(均P<0.05)。结论前炎止痛贴联合前列清瘀汤治疗慢性前列腺炎,能够明显改善患者临床症状,治疗效果优于单纯中药治疗、单纯脐贴治疗和口服宁泌泰治疗,其机制可能与提高前列腺按摩液(expressed prostatic secretion,EPS)中Zn2+和PSA水平有关。     

不同剂量和疗程伐昔洛韦治疗复发性生殖器疱疹的随机双盲研究

目的 比较不同剂量和疗程伐昔洛韦治疗复发性生殖器疱疹的疗效和安全性。方法 选择复发性生殖器疱疹为研究对象,采用多中心、随机、双盲、对照临床研究。试验组伐昔洛韦每天2次,每次500 mg,口服5天,对照组伐旨洛韦每天2次,每次300 mg,口服7天。分别于用药前及用药后第1天、第2天取疱液或创面分泌物行疱疹病毒细胞培养,并于用药后第1、2、7天随访观察疗效和不良反应。结果 入组142例,全分析集(FAS)分析142例,符合方案集(PPS)分析133例。治疗后第1、2、7天,试验组和对照组的症状体征积分下降值及有效率比较差异均无统计学意义(P>0.05)。FAS集分析单纯疱疹病毒(HSV)的培养阳性率,治疗后第1天试验组由87.50%下降到28.85%,对照组由92.86%下降到54.55%,两组间差异有统计学意义(P=0.007)。PPS集分析HSV的培养阳性率,治疗后第1天试验组由90.00%下降到28.00%,对照组由92.59%下降到55.56%,两组比较差异有统计学意义(P=0.005)。试验组和对照组不良反应发生率分别为0%和4.23%。结论 加大伐昔洛韦用量治疗复发性生殖器疱疹能显著提高治疗后第1天HSV的清除率,缩短HSV在皮损局部的存在时间。     

Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study

BACKGROUND: There has been considerable interest in traditional Chinese herbal medicine (TCHM) as a treatment for atopic dermatitis (AD). A twice-daily concoction of an ancestral formula containing five herbs has been found to be beneficial in an open study. OBJECTIVES:To assess the efficacy and tolerability of the concoction in children with AD. METHODS: Following a 2-week run-in period, children with long-standing moderate-to-severe AD were randomized to receive a 12-week treatment with twice-daily dosing of three capsules of either TCHM or placebo. The SCORing of Atopic Dermatitis (SCORAD) score, Children's Dermatology Life Quality Index (CDLQI), allergic rhinitis score, and requirement for topical corticosteroid and oral antihistamine were assessed before and at weeks 4, 8, 12 and 16 after treatment. Adverse events, tolerability, haematological and biochemical parameters were monitored during the study. RESULTS: Eighty-five children with AD were recruited. Over 12 weeks, the mean SCORAD score fell from 58.3 to 49.7 in the TCHM group (n = 42; P = 0.003) and from 56.9 to 46.9 in the placebo group (n = 43; P = 0.001). However, there was no significant difference in the scores at the corresponding time points between the two groups. The CDLQI in TCHM-treated patients was significantly improved compared with patients receiving placebo at the end of the 3-month treatment and 4 weeks after stopping therapy (P = 0.008 and 0.059, respectively). The total amount of topical corticosteroid used was also significantly reduced by one-third in the TCHM group (P = 0.024). No serious adverse effects were observed between the groups. CONCLUSIONS: The TCHM concoction is efficacious in improving quality of life and reducing topical corticosteroid use in children with moderate-to-severe AD. The formulation was palatable and well tolerated.